Covid-19 vaccines: In the rush for regulatory approval, do we need more data?
Peter Doshi
Abstract
After rollout under emergency authorisation, manufacturers of covid-19 vaccines now have their sights on regulatory approval. But what’s the rush, asks <b>Peter Doshi</b>, and is just six months of data from now unblinded trials acceptable?
Topics & Concepts
Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AuthorizationMedicineDrug approvalSightVirologyInternet privacyComputer securityOutbreakComputer scienceInfectious disease (medical specialty)PharmacologyDiseasePathologyDrugPhysicsAstronomySARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyInfluenza Virus Research Studies